Zobrazeno 1 - 10
of 21
pro vyhledávání: '"Palash, Asawa"'
Autor:
Muath, Abdeen, Urwat Til, Vusqa, Palash, Asawa, Kiley, Felton, Derek, Rinchuse, Cyrus, Khan, Yazan, Samhouri, John, Lister
Publikováno v:
Anti-Cancer Drugs. 33:1167-1170
Venetoclax, a highly selective Bcl-2 inhibitor, is an orally bioavailable drug that has been approved as first-line therapy for chronic lymphocytic leukemia (CLL) in combination with obinutuzumab, as well as monotherapy in the setting of relapsed CLL
Autor:
Rahul Karna, Smit S Deliwala, Balasubramanian Ramgopal, Palash Asawa, Rahul Mishra, Babu P Mohan, Thejus Jayakrishnan, Dheera Grover, Tanisha Kalra, Jaideep Bhalla, Ushasi Saraswati, Manesh K Gangwani, Manish Dhawan, Douglas G Adler
Publikováno v:
Immunotherapy.
Introduction: Combined immune checkpoint inhibitors can cause gastrointestinal adverse events. Methods: We performed a meta-analysis of pooled colonic, hepatic and pancreatic treatment-related adverse events of combined ICI. Results: 53 trials report
Publikováno v:
Journal of Gastrointestinal Cancer.
The neoadjuvant rectal cancer (NAR) score is a prognostic tool for locally advanced rectal cancer (LARC) treated with total neoadjuvant therapy (TNT). It has been previously validated as an endpoint that predicts survival more accurately than patholo
Publikováno v:
Hematology/oncology and stem cell therapy. 15(3)
Adoptive cellular therapies have revolutionized the management of hematologic malignancies, particularly lymphoma and multiple myeloma. These therapies targeting disease-specific antigens, such as CD19 in lymphoma and B cell maturation antigen in mul
Publikováno v:
Anticancer research. 42(8)
Chimeric antigen receptor (CAR) T-cell therapy has revolutionized the treatment of various B-cell malignancies. However, it can cause serious adverse effects like immune effector cell-associated neurotoxicity syndrome (ICANS). ICANS is attributed to
Autor:
Palash Asawa, Veli Bakalov, Pragnan Kancharla, Stephen Abel, Zena Chahine, Dulabh K. Monga, Alexander V. Kirichenko, Rodney E. Wegner
Publikováno v:
International journal of colorectal disease. 37(5)
BackgroundThe prognostic value of the KRAS proto-oncogene mutation in colorectal cancer has been debated. Herein, we analyzed the National Cancer Database (NCDB) to assess the role of KRAS mutation as a prognostic marker in patients with locally adva
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners. 28(7)
Publikováno v:
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
Introduction Multiple myeloma (MM) is the second most common hematological malignancy, accounting for 1% of all cancers, with median age of diagnosis between 66–70 years. MM remains incurable despite advances in treatment over time. Lenalidomide is
Autor:
Rahul Karna, Palash Asawa, Tanveer Ud-Din Mian, Adeel Nasrullah, Amresh Raina, Hayah Kassis George
Publikováno v:
SSRN Electronic Journal.
Autor:
Clara Grayhack, Palash Asawa, Adriani Cherico, Jillian Dolan, Anuranita Gupta, Shivani Shah, Ryan Sweeney, Amy Whitsel, Ronald Thomas, Rama Bhagavatula, Yazan Samhouri
Publikováno v:
American Journal of Obstetrics and Gynecology. 228:S113